A clinical trial testing mosliciguat, an inhaled therapy for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), has wrapped up enrollment, and in less than one year since treating the first participant. That announcement was made by Pulmovant, the company developing the drug…
Cereno Scientific announced it will broaden development of its experimental treatment CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno had previously focused development of CS014 on idiopathic pulmonary fibrosis (IPF), a condition marked by progressive scarring (fibrosis) of the lungs with no known…
Artificial intelligence (AI) tools developed by Etiometry may help to predict, among other outcomes, the length of a patient’s hospital stay following surgery among people with chronic thromboembolic pulmonary hypertension (CTEPH). As such, these tools could potentially be used to improve patient care, and better monitor post-surgery recovery,…
A life-support machine that temporarily replaces the heart and lungs — known as extracorporeal membrane oxygenation (ECMO) — boosts survival among pregnant women who develop severe pulmonary arterial hypertension (PAH). That’s according to a case series and literature review that found ECMO use in pregnancy-related PAH has improved survival…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
